Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 8,601–8,700 of 15,747
Wollschläger, D., Gianicolo, E., Blettner, M., Hamann, R., Herm-Stapelberg, N., & Schoeps, M. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00825-6 · Cited by 7
“Clinical trials have demonstrated the efficacy of COVID-19 vaccines in preventing symptomatic and severe disease in a controlled environment [3].”
BackgroundBordry, N., Addeo, A., Jaksic, C., Dutoit, V., Roux-Lombard, P., Shah, D., Shah, P., Gayet-Ageron, A., Friedlaender, A., Bugeia, S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103699 · Cited by 6
Ali, G. G. M. N., Rahman, M. M., Hossain, A., Rahman, M. S., Paul, K. C., Thill, J., & Samuel, J. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3849138 · Cited by 6
COVID-19 vaccine trials and sex-disaggregated data
Hussain, M., Fatima, M., Iqbal, S. M., Asif, M., Saadullah, M., Kashif-ur-Rehman, Mukhtar, I., Khan, I. A., Parveen, S., Fayyaz, T., et al. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2015331 · Cited by 5
“reports those included sex-disaggregated primary outcomes data should be applauded [30,31].”
BackgroundSisteré-Oró, M., Wortmann, D. D. J., Andrade, N., Aguilar, A., Casas, C. M. D. L., Casabal, F. G., Torres, S., Salinas, E. B., Soler, L. R., Arcas, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908108 · Cited by 7
“They are inducing virus-specific antibody and cellular immunity, and about a 95% protection from SARS-CoV-2-induced disease (12, 13).”
BackgroundT cell responses to adenoviral vectors expressing the SARS-CoV-2 nucleoprotein.
Hasanpourghadi, M., Novikov, M., Ambrose, R., Chekaoui, A., Newman, D., Zhou, X., & Ertl, H. C. J. (2021) · PubMed · Cited by 6
COVID-19 Therapeutics and Considerations for Pregnancy
Joseph, N. T., & Collier, A.-R. Y. (2022) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2022.10.018 · Cited by 7
Stroffolini, T., Ciancio, A., Federico, A., Benigno, R., Colloredo, G., Lombardi, A., Niro, G. A., Verucchi, G., Ferrigno, L., Gioli, F., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.11.016 · Cited by 6
Sannier, G., Nicolas, A., Dubé, M., Marchitto, L., Nayrac, M., Tastet, O., Chatterjee, D., Tauzin, A., Lima-Barbosa, R., Laporte, M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100955 · Cited by 8
Wang, H., Lauwers, H., Gontsarik, M., Chen, Y., Sanders, N. N., Cheng, M. H. Y., Geest, B. G. D., & Zhong, Z. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501788 · Cited by 8
Yoon, D., Jeon, H., Noh, Y., Choe, Y. J., Choe, S., Jung, J., & Shin, J. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e170 · Cited by 9
Jain, V., Doernberg, S. B., Holubar, M. K., Huang, B., Marquez, C., Brown, L. B., Rubio, L., Sample, H. A., Bollyky, J., Padda, G., et al. (2021) · medRxiv · doi:10.1101/2021.02.19.21251993 · Cited by 6
Lagousi, T., Routsias, J. G., Mavrouli, M. D., Papadatou, I., Geropeppa, M., & Spoulou, V. I. (2022) · Vaccines · doi:10.3390/vaccines10081210 · Cited by 7
“Despite its high efficacy in immunocompetent individuals [2], the duration of BNT162b2 protection remains to be defined.”
BackgroundCleary, D. W., Campling, J., Lahuerta, M., Hayford, K. T., Southern, J., Gessner, B. D., Lo, S. W., Bentley, S. D., Faust, S. N., & Clarke, S. C. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00224-24 · Cited by 7
Cvetković, M., Pantić, N., Virijević, M., et al. (2023) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.17719 · Cited by 6
Rahmani, K., Shavaleh, R., Forouhi, M., Disfani, H. F., Kamandi, M., Dezfuli, A. A., Oskooi, R. K., Foogerdi, M., & Soltani, M. (2021) · medRxiv · doi:10.1101/2021.11.03.21265819 · Cited by 5
COVID-19 Vaccination Preferences Among Non-Chinese Migrants in Hong Kong: Discrete Choice Experiment
Asim, S., Wang, K., Nichini, E., Yip, F. F., Zhu, L., Fung, E. H. C., Zeng, Y., Fang, Z., Cheung, A. W.-L., Wong, E. L., et al. (2023) · JMIR Public Health and Surveillance · doi:10.2196/40587 · Cited by 6
A Case of Diffuse Alveolar Hemorrhage With COVID-19 Vaccination
Sharma, A. E., Upadhyay, B., Banjade, R., et al. (2022) · Cureus · doi:10.7759/cureus.21665 · Cited by 6
“Systemic adverse events have been seen usually after the second dose of vaccine within two days of the second dose [2,11].”
BackgroundmRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond
Prakash, S. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00849-1 · Cited by 9
Smith, B., Farakh, F., Hanif, A., Tunio, J. H., & Tunio, S. N. J. (2025) · Vaccines · doi:10.3390/vaccines13080861 · Cited by 7
“Following rigorous review, regulatory agencies granted Emergency Use Authorizations (EUAs) in December 2020 for the Pfizer-BioNTech and Moderna vaccines, initiating mass vaccination campaigns and representing a significant milestone in pandemic control [1,28].”
InfluentialTakano, T., Hirose, M., Yamasaki, Y., Hara, M., Okada, T., & Kunishima, H. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.02.002 · Cited by 7
“738 which is consistent with a previous report of adverse reactions [10].”
Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
Goda, K., Kenzaka, T., Yahata, S., Okayama, M., & Nishisaki, H. (2022) · Vaccines · doi:10.3390/vaccines10081232 · Cited by 6
“and among younger people than among older people after immunization against COVID19 [3,8], to our knowledge, no previous studies have investigated the impact of first-dose adverse reactions on second-dose adverse reactions.”
BackgroundResultInfluentialHara, M., Furue, T., Fukuoka, M., Iwanaga, K., Matsuishi, E., Miike, T., Sakamoto, Y., Mukai, N., Kinugasa, Y., Shigyo, M., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2226575 · Cited by 5
Lyski, Z. L., Kim, M. S., Lee, D. X., Sampson, D. A., Raué, H.-P., Raghunathan, V. M., Ryan, D., Brunton, A. E., Slifka, M. K., Messer, W. B., et al. (2022) · Case Reports in Hematology · doi:10.1155/2022/6831640 · Cited by 5
“Although Subject 1 did have an immune response, antibody levels were relatively low as compared to some of the levels observed in immunocompetent postvaccine populations [16] and certain CLL populations [4].”
BackgroundResultDesign and characterization of chimeric Rabies-SARS-CoV-2 virus-like particles for vaccine purposes
Garay, E., Fontana, D., Villarraza, J., Fuselli, A., Gugliotta, A., Antuña, S., Tardivo, M. B., Rodríguez, M. C., Gastaldi, V., Battagliotti, J. M., et al. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12545-w · Cited by 7
Lauro, M. L., Bowman, A. M., Smith, J. P., Gaye, S. N., Acevedo‐Skrip, J., DePhillips, P., & Loughney, J. W. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00764-4 · Cited by 7
“This renders the current methodologies incompatible with many prominent vaccines such as mRNA vaccines and others utilizing RNA-based viruses as they contain high levels of RNA (2, 3, 25).”
Tamayo-Velasco, Á., López-Herrero, R., Gómez-García, L. M., et al. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.04.005 · Cited by 6
Liu, T., Yin, X., Liu, Q., & Hounye, A. H. (2023) · Alexandria Engineering Journal · doi:10.1016/j.aej.2023.11.068 · Cited by 6
Expanding global access to mRNA vaccines
Eshaghi, B., Langer, R., & Jaklenec, A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00424-8 · Cited by 9
“The success of mRNA vaccines during the COVID-19 pandemic demonstrated their speed of development, scalable manufacturing, adapt-ability to viral variants and strong safety profile 1–5 .”
Patients with IBD have a more cautious attitude towards COVID-19 vaccination
Hu, S., Liu, J., Li, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1077308 · Cited by 6
“However, the inclusion criteria of vaccines that are currently on the market do not include patients with immune diseases or receiving immunosuppressive therapy (29, 30).”
BackgroundSharma, B., Racey, C. S., Booth, A., Albert, A., Smith, L., Gottschlich, A., Goldfarb, D. A., Murray, M. C. M., Galea, L. A. M., Kaida, A., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100208 · Cited by 8
“[12] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
BackgroundOral non-viral gene delivery platforms for therapeutic applications
Ghaemi, A., Azghandi, M. V., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123198 · Cited by 6
Cardio-oncology Training in the COVID-19 Era
Feldman, S. A., Liu, J., Steingart, R. M., & Gupta, D. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00855-y · Cited by 6
Singhal, A. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2011.05136 · Cited by 8
Clinical data to be used as a foundation to combat Covid-19 vaccine hesitancy
Smith, R. G. (2021) · Journal of Interprofessional Education & Practice · doi:10.1016/j.xjep.2021.100483 · Cited by 6
Differential Dynamic Behavior of Prefusion Spike Proteins of SARS Coronaviruses 1 and 2Preprint
Kumar, V. G., Ogden, D. S., Isu, U. H., Polasa, A., Losey, J., & Moradi, M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.25.424008 · Cited by 7
Paschou, S. Α., Karalis, V. D., Ψαλτοπούλου, Θ., Charitaki, I., Sklirou, A. D., Iconomidou, V. A., Vasileiou, V., Kassi, G., Vryonidou, A., Kokkinos, A. D., et al. (2022) · HORMONES · doi:10.1007/s42000-022-00405-7 · Cited by 7
Liu, H., Xu, Z., Karsidag, I., Wang, P., & Weng, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1689507 · Cited by 8
Off-Label Prescription of COVID-19 Vaccines in Children: Clinical, Ethical, and Legal Issues
deSante-Bertkau, J. E., Knilans, T. K., Persad, G., Zettler, P. J., Lynch, H. F., & Antommaria, A. H. M. (2021) · PEDIATRICS · doi:10.1542/peds.2021-054578 · Cited by 6
(Mis)Communication of COVID‐19 vaccine benefits and harms
Mercuri, M., & Gafni, A. (2022) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13655 · Cited by 7
Interference of p53:Twist1 interaction through competing nanobodies
D'Agostino, S., Mazzega, E., Praček, K., Piccinin, S., Pivetta, F., Armellin, M., Fortuna, S., Maestro, R., & de Marco, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.160 · Cited by 8
A Case of Transient Visual Field Defect following Administration of Pfizer-BioNTech COVID-19 Vaccine
Sezenöz, A. S., Güngör, S. G., & Kibaroğlu, S. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2055578 · Cited by 6
“the second dosage and continue for a few days, starting between the first and second day following the injection.(4)”
BackgroundGuzmán (2022) · Journal of clinical outcomes management · doi:10.12788/jcom.0108 · Cited by 6
Mavrovouniotis, I., Fylaktou, A., Stangou, M. J., Ouranos, K., Λιούλιος, Γ., Evgenikaki, E., Exindari, M., & Gioula, G. (2023) · Life · doi:10.3390/life13020474 · Cited by 7
Formosa, A., Acton, E., Lee, A. H., Turgeon, P. J., Izhar, S., Plant, P. J., Tsoporis, J. N., Soussi, S., Trahtemberg, U., BAKER, A. J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286871 · Cited by 8
“While the advent of vaccination has had a remarkable effect in preventing serious illness [6, 7], vaccinated individuals can suffer breakthrough infections with high illness severity [4].”
BackgroundVirus-associated ribozymes and nano carriers against COVID-19
Dönmüş, B., ÜNAL, S., Kırmızıtaş, F. C., & Laçin, N. T. (2021) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2021.1890103 · Cited by 6
Self-citationFerrari, D., Clementi, N., Mancini, N., & Locatelli, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.010 · Cited by 6
Kared, H., Jyssum, I., Alirezaylavasani, A., Egner, I. M., Tran, T. T., Tietze, L., Lund, K. P., Tveter, A. T., Provan, S. A., Ørbo, H. S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1296273 · Cited by 7
Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19
LANDAY, A. L., Bartley, J. M., Banerjee, D., Hargis, G. R., Haynes, L., Keshavarzian, A., Kuo, C., Kwon, O. S., Li, S., Li, S., et al. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.695218 · Cited by 7
Toya, T., Atsuta, Y., Sanada, T., Honda, T., Sadato, D., Sekiya, N., Kogure, H., Takakuwa, S., Onai, D., Shingai, N., et al. (2022) · Cancer Science · doi:10.1111/cas.15603 · Cited by 5
Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
Gasperina, D. D., Veronesi, G., Castelletti, C. M., Varchetta, S., Ottolini, S., Mele, D., Ferrari, G., Shaik, A. K. B., Celesti, F., Dentali, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813728 · Cited by 7
Kawaguchi, K., Nguyen, L. B. T., Kinoshita, M., Abe, N., Oba, M., Abe, H., Sudo, K., Inoue, K., Uchida, S., & Sawa, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113860 · Cited by 9
Machine learning-driven molecular engineering of nucleic acids
Shi, Q., Lv, H., Wang, F., Fan, C., & Li, M. (2026) · Chemical Society Reviews · doi:10.1039/d5cs01091h · Cited by 11
Geldof, J., Truyens, M., Sabino, J., Ferrante, M., Lambert, J., Lapeere, H., Hillary, T., Laethem, A. V., de Vlam, K., Verschueren, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126351 · Cited by 6
Declined Humoral Immunity of Kidney Transplant Recipients to SARS-CoV-2 Vaccines
Mahallawi, W. H., Alharbi, W. A., Aloufi, S. A., Ibrahim, N. A., Abdelrahman, M. M., Alhomayeed, B. A., Aboonq, M. S., Alqahtani, S. A. M., Rajih, E. S., Bakhsh, A. M., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s408686 · Cited by 7
“The vaccines’ immunogenicity has been well demonstrated in the general population.(15) However, recent investigations have shown a lesser immune response in transplant recipients, but the findings vary widely between studies.”
ResultRodrigues‐Jesus, M. J., Favaro, M. T. D. P., Venceslau-Carvalho, A. A., de Castro‐Amarante, M. F., Almeida, B. D. S., Silva, M. D. O., Andreata‐Santos, R., Barbosa, C. G., Brito, S. C. M., Freitas-Junior, L. H., et al. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102595 · Cited by 6
Bermingham, C., Morgan, J., Ayoubkhani, D., Glickman, M., Islam, N., Sheikh, A., Sterne, J., Walker, A., & Nafilyan, V. (2021) · medRxiv · doi:10.1101/2021.07.12.21260385 · Cited by 11
“For the BNT162b2 mRNA vaccine (Pfizer-BioNTech), 95% efficacy was reported against laboratory-confirmed COVID-19 [2].”
ResultDoes the COVID-19 Vaccination Reduce the Risk to Transmit SARS-CoV-2 to Others?
Kampf, G. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-61939-7_14 · Cited by 7
Kobara, I. D. L. R., Jayewickreme, R., Lee, M. J., Wilk, A. J., Biobank, S. C.-1., Blomkalns, A. L., Nadeau, K. C., Yang, S. S., Rogers, A. J., & Blish, C. A. (2025) · Nature Immunology · doi:10.1038/s41590-025-02341-1 · Cited by 11
Hospitalist perspectives on barriers to recommend and potential benefit of the COVID-19 vaccine
Dugani, S. B., Geyer, H. L., Maniaci, M. J., Fischer, K. M., Croghan, I. T., Coons, T. J., Canan, E. L., & Burton, M. C. (2021) · Hospital Practice · doi:10.1080/21548331.2021.1914465 · Cited by 7
Diaphragmatic Dysfunction due to Neuralgic Amyotrophy After SARS-CoV-2 Vaccination: A Case Report
Kang, J., & Cho, J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e283 · Cited by 6
Russo, E., Corrao, S., Gaudio, F. D., Alberti, G., Čaprnda, M., Kubatka, P., Kružliak, P., Miceli, V., Conaldi, P. G., Borlongan, C. V., et al. (2023) · Cells · doi:10.3390/cells12121664 · Cited by 7
Laham, G., Martínez, A. P., Rojas, W., Amaya, L., Abib, A., Echegoyen, N., Diaz, C. H., Lucero, A., Martelli, A., Videla, C. M., et al. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01446-2 · Cited by 7
Majid, L., Radhakrishnan, S., Vignesh, R., & Muthukumarasamy, R. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00990 · Cited by 6
Zhao, Q., Liang, M., & Ai, Y. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.137953 · Cited by 6
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UKPreprint
Buckell, J., Jones, J. W., Matthews, P. C., et al. (2021) · medRxiv · doi:10.1101/2021.11.15.21266255 · Cited by 6
Farias, J. P., Andreata‐Santos, R., Brito, R. D. D. S., Souza, M. S., Fogaça, M. M. C., Pinheiro, J. R., da Cruz, E. F., Liang, W., Simões, R. D. C., Luiz, W. B., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02857-23 · Cited by 7
Lorent, D., Nowak, R., Luwański, D., Pisarska-Krawczyk, M., Figlerowicz, M., & Zmora, P. (2022) · Vaccines · doi:10.3390/vaccines10101576 · Cited by 8
Glaser, G. E., Lara, O. D., Pothuri, B., Grimaldi, C. G., Prescott, L. S., Mastroyannis, S. A., Kim, S., ElNaggar, A. C., Torres, D., Conrad, L. B., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.09.017 · Cited by 6
Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant
Atanackovic, D., Luetkens, T., Avila, S. V., Hardy, N. M., Lutfi, F. U., Sanchez‐Petitto, G., Mause, E. R. V., Glynn, N. M., Mannuel, H. D., Alkhaldi, H., et al. (2021) · Vaccines · doi:10.3390/vaccines9070737 · Cited by 6
Al-Abdulla, O., Kallström, A., Kauhanen, J., & Valderrama, C. (2022) · Zoonotic Diseases · doi:10.3390/zoonoticdis2020006 · Cited by 8
“The World Health Organization (WHO) declared a global pandemic on 11 March 2020 [1].”
BackgroundUrgent COVID-19 Vaccination of Healthcare Workers via a Quality Improvement Initiative
Baumer-Mouradian, S. H., Collins, S., Lausten, T., et al. (2021) · Pediatric Quality and Safety · doi:10.1097/pq9.0000000000000532 · Cited by 6
A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan
He, Y., Yu, W., Shen, L., Yan, W., Xiao, L., Qi, J., & Hu, T. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.180 · Cited by 7
Morales‐Núñez, J. J., García‐Chagollán, M., Muñóz-Valle, J. F., Díaz-Pérez, S. A., Torres-Hernández, P. C., Rodríguez-Reyes, S. C., Santoscoy‐Ascencio, G., de Quevedo, J. J. S. G., & Hernández‐Bello, J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s374304 · Cited by 7
“COVID-19 is the great pandemic of the 21st century caused by the SARS-CoV-2 virus.1 Immunization through vaccines is the most efficient measure to prevent emerging and re-emerging infectious diseases in the human population;2 however, its effectiveness depends on the developed immune response.3 The BNT162b2 (Pfizer-Bi…”
BackgroundInfluentialSheehan, N., Botta, F., & Leonelli, S. (2024) · Data Science Journal · doi:10.5334/dsj-2024-029 · Cited by 11
The effect of SARS-CoV-2 BNT162b2 vaccine on the symptoms of women with endometriosis
Gilan, A., Laster-Haim, S., Rottenstreich, A., Porat, S., Lessans, N., Saar, T. D., & Dior, U. P. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06765-0 · Cited by 6
“Even though we found a correlation between the SARSCoV-2 mRNA vaccine and worsening in EAS it should be emphasized that COVID-19 is an extremely contagious virus that could lead to a wide range of severe symptoms [25] and mortality even in healthy young people [26] and that the vaccine is the one proven way to prevent…”
Distinguishing Swine Flu (H1N1) from COVID-19: Clinical, Virological, and Immunological Perspectives
Batta, I., Kaur, T., & Agrawal, D. K. (2023) · Archives of Microbiology & Immunology · doi:10.26502/ami.936500125 · Cited by 9
“They use innovative mRNA or viral vector technologies to trigger an immune response [43-45].”
BackgroundKhalil, M., Bonfrate, L., Ciaula, A. D., Portincasa, P., The LEITvax Group^, Abdallah, H., Capurso, M., Galerati, I., Hayek, S., Khalifeh, H., et al. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03321-9 · Cited by 6
“The prevalence of this symptom in the Lebanese cohort was also markedly lower than that recorded in other European cohorts, which ranges from 70 to 80% of subjects [18].”
ResultAndersen, K. M., McGrath, L. J., Reimbaeva, M., Mendes, D., Nguyen, J. L., Rai, K. K., Tritton, T., Tsang, C., Malhotra, D., & Yang, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-073866 · Cited by 6
Bier, C., Edelmann, A., Theil, K., Schwarzer, R., Deichner, M., Gessner, A., Hiergeist, A., Rentschler, U., Gohl, P., Kuchta, A. L., et al. (2021) · medRxiv · doi:10.1101/2021.05.05.21254713 · Cited by 6
“[7-11], small molecule antivirals [12, 13], immune modulators [14, 15], and other non-”
BackgroundChemaitelly, H. S., Akhtar, N., Jerdi, S. A., Kamran, S., Joseph, S., Morgan, D., Uy, R. S., Abid, F. B., Al‐Khal, A., Abou‐Samra, A., et al. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2596676 · Cited by 6
Patel, N., Bouchard, J. L., Oliver, M. B., Badowski, M. E., Carreno, J. J., & the Society of Infectious Diseases Pharmacists (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2622 · Cited by 5
Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin
Singh, R., & Freeman, E. E. (2022) · Current Dermatology Reports · doi:10.1007/s13671-022-00370-9 · Cited by 7
Harmonizing the collection of solicited adverse events in prophylactic vaccine clinical trials
Cheuvart, B., Spiessens, B., van Heesbeen, R., Hung, D., Andrade, C., Korejwo, J., & Tavares-Da-Silva, F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2262571 · Cited by 6
Matrajt, L., Janes, H., Schiffer, J. T., & Dimitrov, D. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab341 · Cited by 6
Experiences and perspectives of cancer stakeholders regarding COVID‐19 vaccination
Bartley, N., Havard, P. E., Butow, P. N., Shaw, J., & COVID‐19 Cancer Stakeholder Authorship Group (2022) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13808 · Cited by 5
Borrowing historical information for non-inferiority trials on Covid-19 vaccines
Santis, F. D., & Gubbiotti, S. (2022) · The International Journal of Biostatistics · doi:10.1515/ijb-2021-0120 · Cited by 6
Hung, C., Hsiao, S.-H., Huang, C., Chang, C., Chen, G.-Y., Huang, Y.-L., Dutta, A., & Huang, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204314 · Cited by 7
“ART suppresses the virus and improves immune function to turn the disease into a chronic condition with high life expectancy in PLWH (13).”
BackgroundRobust anti-SARS-CoV2 single domain antibodies cross neutralize multiple viruses
Singh, S., Dahiya, S., Singh, Y. J., Beeton, K., Jain, A., Sarkar, R., Dubey, A., Tehseen, A., & Sehrawat, S. (2022) · iScience · doi:10.1016/j.isci.2022.104549 · Cited by 7
Grøsland, M., Larsen, V. B., Telle, K. E., & Gjefsen, H. M. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08541-x · Cited by 7
“Observational studies on vaccine effectiveness have suggested that mRNA vaccines reduce hospitalization with more than 85 percent for the Alpha and Delta variant [9, 10], while vaccine efficacy has been shown to be even higher [11].”
BackgroundCOVID-19 vaccine: the gender disparity
Corda, V., Murgia, F., & Monni, G. (2021) · Journal of Perinatal Medicine · doi:10.1515/jpm-2021-0246 · Cited by 6
Retinal Vascular Occlusion after Severe Acute Respiratory Syndrome Coronavirus Vaccination
Singh, R. B., Parmar, U. P. S., Gupta, R., Garcia, A. J. V., Cho, W., Singh, K. P., & Agarwal, A. K. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100354 · Cited by 6
CD44-targeted lipid nanoparticles for enhanced CRISPR/Cas9 delivery in cancer gene editing
Zeng, Y., Zhao, G., Wu, S., Bochuan, H., Forn‐Cuní, G., Knol, R. A., Ghalbzouri, A. E., Snaar-Jagalska, E. B., & Kros, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114598 · Cited by 8
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.